source
- Eli Lilly halts early-stage obesity drug LY4064912 after failing to meet development criteriaEli Lilly announced it is ending development of its early-stage obesity candidate, LY4064912, after the phase 1 study did not achieve the company’s expectations. The first‑in‑human trial enrolled…
- AstraZeneca's Etcamah fails late-stage trial for early-stage breast cancer useAstraZeneca announced that its newly approved breast cancer therapy, Etcamah, did not meet its primary goals in a pivotal study aimed at expanding the drug's label. The trial evaluated Etcamah in…